X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1152) 1152
humans (961) 961
oncology (578) 578
phase-2 (570) 570
female (480) 480
phase-2 trial (451) 451
male (449) 449
middle aged (405) 405
aged (336) 336
hematology (298) 298
open-label (297) 297
adult (289) 289
cancer (287) 287
treatment outcome (259) 259
chemotherapy (234) 234
therapy (225) 225
animals (220) 220
care and treatment (199) 199
pharmacology & pharmacy (193) 193
analysis (174) 174
survival (155) 155
aged, 80 and over (154) 154
bortezomib (144) 144
antineoplastic combined chemotherapy protocols - therapeutic use (142) 142
antineoplastic agents - therapeutic use (139) 139
research (131) 131
drug therapy (129) 129
immunotherapy (129) 129
patients (129) 129
multiple myeloma (128) 128
multiple myeloma - drug therapy (127) 127
trial (126) 126
multicenter (123) 123
medicine & public health (119) 119
clinical trials (116) 116
health aspects (115) 115
prognosis (112) 112
double-blind (110) 110
retrospective studies (107) 107
safety (105) 105
efficacy (101) 101
abridged index medicus (97) 97
oxidative stress (97) 97
metastasis (95) 95
dexamethasone (91) 91
mutation (91) 91
melanoma (88) 88
combination (87) 87
medical research (85) 85
mice (85) 85
tumors (85) 85
ipilimumab (81) 81
phase-2 enzymes (81) 81
article (80) 80
young adult (80) 80
disease-free survival (78) 78
recurrence (78) 78
dose-response relationship, drug (77) 77
hepatitis c virus (76) 76
apoptosis (74) 74
hematology, oncology and palliative medicine (72) 72
rituximab (71) 71
toxicity (71) 71
transplantation (71) 71
antineoplastic agents - adverse effects (70) 70
immunology (70) 70
antiviral agents - therapeutic use (69) 69
biochemistry & molecular biology (69) 69
cell lung-cancer (68) 68
hepatitis c (68) 68
adolescent (67) 67
review (67) 67
gastroenterology & hepatology (66) 66
survival analysis (66) 66
medicine, general & internal (64) 64
drug therapy, combination (63) 63
antineoplastic agents - administration & dosage (62) 62
lenalidomide (62) 62
nf-e2-related factor 2 - metabolism (61) 61
pembrolizumab (61) 61
refractory myeloma (61) 61
risk factors (61) 61
hepatitis c, chronic - drug therapy (60) 60
thalidomide (60) 60
antineoplastic combined chemotherapy protocols - adverse effects (59) 59
cancer therapies (59) 59
disease (59) 59
nivolumab (59) 59
ribavirin (59) 59
follow-up studies (58) 58
patient outcomes (58) 58
usage (58) 58
randomized phase-2 (57) 57
genetic aspects (55) 55
medicine, experimental (55) 55
antibodies, monoclonal - therapeutic use (54) 54
sofosbuvir (54) 54
disease progression (53) 53
medicine, research & experimental (53) 53
medical prognosis (52) 52
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 9, pp. 983 - 991
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 268 - 279
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 6, pp. 1131 - 1140.e5
Journal Article
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 4, pp. 504 - 507
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1232 - 1239
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 687 - 693
Abstract Background Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic... 
CNS | Osimertinib | Brain metastases | NSCLC | GEFITINIB | brain metastases | METASTASES | WHOLE-BRAIN RADIOTHERAPY | PHASE-2 | CELL LUNG-CANCER | THERAPY | STEREOTACTIC RADIOSURGERY | ONCOLOGY | osimertinib | RESISTANCE | INHIBITORS | ERLOTINIB | Index Medicus
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 04/2011, Volume 300, Issue 4, pp. H1133 - H1140
Ungvari Z, Bailey-Downs L, Gautam T, Jimenez R, Losonczy G, Zhang C, Ballabh P, Recchia FA, Wilkerson DC, Sonntag WE, Pearson K, de Cabo R, Csiszar A. Adaptive... 
Endothelial dysfunction | Oxidative stress | Diabetes | KAPPA-B ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | HIGH-FAT DIET | NECROSIS-FACTOR-ALPHA | endothelial dysfunction | TRANSCRIPTION FACTOR NRF2 | INDUCED OXIDATIVE STRESS | PHASE-2 ENZYMES | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | HYDROGEN-PEROXIDE | MITOCHONDRIAL SUPEROXIDE | diabetes | UP-REGULATION | oxidative stress | Adaptation, Physiological | Catalase - pharmacology | Dietary Fats - metabolism | Reactive Oxygen Species - metabolism | Cytoskeletal Proteins - genetics | Antioxidants - metabolism | Male | Aorta - metabolism | NAD(P)H Dehydrogenase (Quinone) - genetics | Coronary Vessels - metabolism | Heme Oxygenase-1 - genetics | Dietary Fats - pharmacology | NF-E2-Related Factor 2 - genetics | Kelch-Like ECH-Associated Protein 1 | Polyethylene Glycols - pharmacology | Membrane Proteins - genetics | Cells, Cultured | Gene Expression Regulation | Hydrogen Peroxide - pharmacology | Mice, Inbred ICR | Hyperglycemia - metabolism | Animals | Endothelium, Vascular - metabolism | NF-E2-Related Factor 2 - metabolism | Acetylcysteine - pharmacology | Adaptor Proteins, Signal Transducing - genetics | Aorta - chemistry | Glutamate-Cysteine Ligase - genetics | Mice | Antioxidants | Physiological aspects | Hyperglycemia | Studies | Rodents | Genes | Glucose | Gene expression | Cells | Index Medicus | Vascular Biology and Microcirculation
Journal Article
Cancer Discovery, ISSN 2159-8274, 11/2018, Volume 8, Issue 11, pp. 1404 - 1421
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs... 
BREAST-CANCER | OLAPARIB | MODELS | ONCOLOGY | DEFICIENT | SUSCEPTIBILITY | PHASE-2 | HOMOLOGOUS RECOMBINATION | BRCA1 | CARCINOMA | GENOME
Journal Article
Journal Article
Journal Article